CompletedPhase 3Phase 4ACTRN12605000611628

DOES USE OF INHALED FLUTICASONE PRIOR TO AN ADENOSINE 5'MONOPHOSPHATE (AMP) BRONCHIAL PROVOCATION TEST AFFECT THE PERCEPTION OF DYSPNOEA?

DOES USE OF INHALED FLUTICASONE PRIOR TO AN ADENOSINE 5'MONOPHOSPHATE (AMP) BRONCHIAL PROVOCATION TEST AFFECT THE PERCEPTION OF DYSPNOEA in asthmatic patients and the development of nasal symptoms?

Sponsor

Woolcock Institute of Medical Research

Enrollment

12 participants

Start Date

Oct 1, 2005

Study Type

Interventional

Conditions

Asthma Allergic Rhinitis

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests whether using inhaled fluticasone (a steroid inhaler) before a breathing test with adenosine affects the test results. It is looking for adults who have been referred for bronchial challenge testing. Participants would use an inhaler before the test and have their airway response measured.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Fluticasone 250mcg inhaled 2 or 14 hours before Adenosine 5' Monophostate Bronchial provocation. Perception of Dyspnoea and Nasal symptoms developed are recorded.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000611628

Related Trials

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

NCT073996659 locations

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

NCT06307665135 locations

Personalized Environment and Genes Study

NCT003412371 location

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

NCT069811693 locations

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589143 locations